Role of TET2 Mutations in Myeloproliferative Neoplasms

被引：24
|
作者：
Pronier, Elodie [2 ,3 ]
Delhommeau, Francois [1 ]
机构：
[1] Univ Paris 06, Hematol Lab, Hop St Antoine, F-75012 Paris, France
[2] Univ Paris 11, Inst Gustave Roussy, UMR 1009, INSERM, Villejuif, France
[3] Univ Paris 07, Paris, France
来源：
CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2012年 / 7卷 / 01期
关键词：
TET2; Mutations; 5-hydroxymethylcytosine; Myeloproliferative neoplasms; Myeloid malignancies; Hematopoietic stem cells; Epigenetics; Pathogenesis; ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ACTIVE DNA DEMETHYLATION; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; ACTIVATING MUTATION; CLONAL ANALYSIS; SELF-RENEWAL; 5-HYDROXYMETHYLCYTOSINE;
D O I：
10.1007/s11899-011-0108-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recently, 5-hydroxymethylcytosine (5-hmC), the 6th base of DNA, was discovered as the product of the hydroxylation of 5-methylcytosine (5-mC) by the ten-eleven translocation (TET) oncogene family members. One of them, TET oncogene family member 2 (TET2), is mutated in a variety of myeloid malignancies, including in 15% of myeloproliferative neoplasms (MPNs). Recent studies tried to go further into the biological and epigenetic function of TET2 protein and 5-hmC marks in the pathogenesis of myeloid malignancies. Although its precise function remains partially unknown, TET2 appears to be an important regulator of hematopoietic stem cell biology. In both mouse and human cells, its inactivation leads to a dramatic deregulation of hematopoiesis that ultimately triggers blood malignancies. Understanding this leukemogenic process will provide tools to develop new epigenetic therapies against blood cancers.
引用
收藏
页码：57 / 64
页数：8
相关论文
共 50 条
  • [31] The Complexity of TET2 Functions in Pluripotency and Development
    Garcia-Outeiral, Vera
    de la Parte, Cristina
    Fidalgo, Miguel
    Guallar, Diana
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 8
  • [32] Mutations, inflammation and phenotype of myeloproliferative neoplasms
    Hermouet, Sylvie
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations
    Sun, Chao
    Zhang, Sujiang
    Li, Jianyong
    LEUKEMIA & LYMPHOMA, 2015, 56 (06) : 1593 - 1598
  • [34] Germline TET2 loss of function causes childhood immunodeficiency and lymphoma
    Spegarova, Jarmila Stremenova
    Lawless, Dylan
    Mohamad, Siti Mardhiana Binti
    Engelhardt, Karin R.
    Doody, Gina
    Shrimpton, Jennifer
    Rensing-Ehl, Anne
    Ehl, Stephan
    Rieux-Laucat, Frederic
    Cargo, Catherine
    Griffin, Helen
    Mikulasova, Aneta
    Acres, Meghan
    Morgan, Neil V.
    Poulter, James A.
    Sheridan, Eamonn G.
    Chetcuti, Philip
    O'Riordan, Sean
    Anwar, Rashida
    Carter, Clive R.
    Przyborski, Stefan
    Windebank, Kevin
    Cant, Andrew J.
    Lako, Majlinda
    Bacon, Chris M.
    Savic, Sinisa
    Hambleton, Sophie
    BLOOD, 2020, 136 (09) : 1055 - 1066
  • [35] Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations
    Szpurka, Hadrian
    Jankowska, Anna M.
    Makishima, Hideki
    Bodo, Juraj
    Bejanyan, Nelli
    Hsi, Eric D.
    Sekeres, Mikkael A.
    Maciejewski, Jaroslaw P.
    LEUKEMIA RESEARCH, 2010, 34 (08) : 969 - 973
  • [36] JAK2 and TET2 Mutation in Polycythemia Vera
    Padda, Jaskamal
    Khalid, Khizer
    Yadav, Jayant
    Almanie, Abdulelah H.
    Mehta, Krutagni Adwait
    Al Hennawi, Hussam
    Boddeti, Nymisha L.
    Campos, Victor Yosef Melt
    Jean-Charles, Gutteridge
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
  • [37] Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
    Nangalia, J.
    Massie, C. E.
    Baxter, E. J.
    Nice, F. L.
    Gundem, G.
    Wedge, D. C.
    Avezov, E.
    Li, J.
    Kollmann, K.
    Kent, D. G.
    Aziz, A.
    Godfrey, A. L.
    Hinton, J.
    Martincorena, I.
    Van Loo, P.
    Jones, A. V.
    Guglielmelli, P.
    Tarpey, P.
    Harding, H. P.
    Fitzpatrick, J. D.
    Goudie, C. T.
    Ortmann, C. A.
    Loughran, S. J.
    Raine, K.
    Jones, D. R.
    Butler, A. P.
    Teague, J. W.
    O'Meara, S.
    McLaren, S.
    Bianchi, M.
    Silber, Y.
    Dimitropoulou, D.
    Bloxham, D.
    Mudie, L.
    Maddison, M.
    Robinson, B.
    Keohane, C.
    Maclean, C.
    Hill, K.
    Orchard, K.
    Tauro, S.
    Du, M-Q
    Greaves, M.
    Bowen, D.
    Huntly, B. J. P.
    Harrison, C. N.
    Cross, N. C. P.
    Ron, D.
    Vannucchi, A. M.
    Papaemmanuil, E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (25) : 2391 - 2405
  • [38] TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms
    Soyer, Nur
    Kaymaz, Burcin Tezcanli
    Ozkan, Melda Comert
    Aktan, Cagdas
    Kucukaslan, Ali Sahin
    Sahin, Fahri
    Kosova, Buket
    Saydam, Guray
    TURKISH JOURNAL OF HEMATOLOGY, 2017, 34 (02) : 174 - 178
  • [39] Focus on the epigenome in the myeloproliferative neoplasms
    Kim, Eunhee
    Abdel-Wahab, Omar
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, : 538 - 544
  • [40] The Potential Equivalents of TET2 Mutations
    Pasca, Sergiu
    Jurj, Ancuta
    Zdrenghea, Mihnea
    Tomuleasa, Ciprian
    CANCERS, 2021, 13 (07)
12345